AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.52-2.81 (-2.59%) ▼|ACN179.03-7.69 (-4.12%) ▼|ADBE257.26-9.25 (-3.47%) ▼|AMAT472.79+18.08 (+3.98%) ▲|AMD505.74+28.17 (+5.90%) ▲|AMGN393.17-44.06 (-10.08%) ▼|AMT175.73-0.12 (-0.07%) ▼|AMZN256.97-1.54 (-0.60%) ▼|AVGO368.56+10.67 (+2.98%) ▲|AXP326.10-0.06 (-0.02%) ▼|BA210.73-1.52 (-0.72%) ▼|BAC62.39-0.29 (-0.46%) ▼|BKNG180.30-12.99 (-6.72%) ▼|BLK1,095.37-21.19 (-1.90%) ▼|BMY64.69-2.13 (-3.19%) ▼|BNY162.85-1.99 (-1.21%) ▼|BRK-B505.83-0.20 (-0.04%) ▼|C136.74-0.98 (-0.71%) ▼|CAT822.48+8.54 (+1.05%) ▲|CL88.41-0.36 (-0.41%) ▼|CMCSA26.33-0.16 (-0.60%) ▼|COF213.96-5.64 (-2.57%) ▼|COP135.04+0.78 (+0.58%) ▲|COST910.18-5.56 (-0.61%) ▼|CRM249.12-10.11 (-3.90%) ▼|CSCO109.17-0.03 (-0.03%) ▼|CVS96.07-0.67 (-0.69%) ▼|CVX209.80+1.20 (+0.58%) ▲|DE680.73-12.80 (-1.85%) ▼|DHR205.23-2.43 (-1.17%) ▼|DIS105.06-0.25 (-0.24%) ▼|DUK121.24+1.02 (+0.85%) ▲|EMR152.15-0.67 (-0.44%) ▼|FDX314.13-8.39 (-2.60%) ▼|GD356.58-2.81 (-0.78%) ▼|GE334.91-2.21 (-0.66%) ▼|GEV971.31+29.36 (+3.12%) ▲|GILD146.64-4.36 (-2.88%) ▼|GM85.79-1.97 (-2.24%) ▼|GOOG335.38+0.07 (+0.02%) ▲|GOOGL338.36-0.10 (-0.03%) ▼|GS1,036.53-2.08 (-0.20%) ▼|HD313.70-7.35 (-2.29%) ▼|HON208.24-1.37 (-0.65%) ▼|IBM232.09-2.80 (-1.19%) ▼|INTC104.47+8.67 (+9.05%) ▲|INTU318.93-13.77 (-4.14%) ▼|ISRG350.16-16.54 (-4.51%) ▼|JNJ269.12-6.11 (-2.22%) ▼|JPM353.51-5.13 (-1.43%) ▼|KO88.36+0.29 (+0.33%) ▲|LIN468.38-9.19 (-1.92%) ▼|LLY1,123.91-25.45 (-2.21%) ▼|LMT536.15+10.87 (+2.07%) ▲|LOW200.80-3.65 (-1.79%) ▼|LRCX320.42+12.77 (+4.15%) ▲|MA570.89-8.32 (-1.44%) ▼|MCD255.81+0.12 (+0.05%) ▲|MDLZ61.63+0.35 (+0.57%) ▲|MDT92.39-1.78 (-1.89%) ▼|META613.48-3.29 (-0.53%) ▼|MMM167.52-1.04 (-0.62%) ▼|MO68.17-0.71 (-1.03%) ▼|MRK148.46-1.87 (-1.24%) ▼|MS216.24-1.48 (-0.68%) ▼|MSFT493.95-5.75 (-1.15%) ▼|MU1,000.26-16.33 (-1.61%) ▼|NEE83.83+0.40 (+0.48%) ▲|NFLX76.77-1.48 (-1.89%) ▼|NKE38.10-0.30 (-0.78%) ▼|NOW134.21-7.05 (-4.99%) ▼|NVDA225.73-4.63 (-2.01%) ▼|ORCL162.52+3.74 (+2.36%) ▲|PEP138.45+0.82 (+0.60%) ▲|PFE27.79-0.66 (-2.32%) ▼|PG145.58-0.86 (-0.59%) ▼|PLTR170.30-4.03 (-2.31%) ▼|PM184.73+2.20 (+1.21%) ▲|QCOM174.09+5.35 (+3.17%) ▲|RTX198.81-1.98 (-0.99%) ▼|SBUX102.01-2.46 (-2.35%) ▼|SCHW106.87-2.42 (-2.21%) ▼|SO88.99+0.88 (+1.00%) ▲|SPG211.88+2.44 (+1.17%) ▲|T25.60-0.08 (-0.31%) ▼|TMO603.02-10.76 (-1.75%) ▼|TMUS181.69+0.17 (+0.09%) ▲|TSLA368.16+14.08 (+3.98%) ▲|TXN258.92+0.48 (+0.19%) ▲|UBER73.13-2.63 (-3.47%) ▼|UNH400.84+3.70 (+0.93%) ▲|UNP288.45-1.17 (-0.40%) ▼|UPS100.48-1.81 (-1.77%) ▼|USB62.49-0.88 (-1.39%) ▼|V368.64-6.43 (-1.71%) ▼|VZ50.41+0.27 (+0.54%) ▲|WFC87.96-2.01 (-2.23%) ▼|WMT106.05-1.09 (-1.02%) ▼|XOM160.66+1.19 (+0.75%) ▲|AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.52-2.81 (-2.59%) ▼|ACN179.03-7.69 (-4.12%) ▼|ADBE257.26-9.25 (-3.47%) ▼|AMAT472.79+18.08 (+3.98%) ▲|AMD505.74+28.17 (+5.90%) ▲|AMGN393.17-44.06 (-10.08%) ▼|AMT175.73-0.12 (-0.07%) ▼|AMZN256.97-1.54 (-0.60%) ▼|AVGO368.56+10.67 (+2.98%) ▲|AXP326.10-0.06 (-0.02%) ▼|BA210.73-1.52 (-0.72%) ▼|BAC62.39-0.29 (-0.46%) ▼|BKNG180.30-12.99 (-6.72%) ▼|BLK1,095.37-21.19 (-1.90%) ▼|BMY64.69-2.13 (-3.19%) ▼|BNY162.85-1.99 (-1.21%) ▼|BRK-B505.83-0.20 (-0.04%) ▼|C136.74-0.98 (-0.71%) ▼|CAT822.48+8.54 (+1.05%) ▲|CL88.41-0.36 (-0.41%) ▼|CMCSA26.33-0.16 (-0.60%) ▼|COF213.96-5.64 (-2.57%) ▼|COP135.04+0.78 (+0.58%) ▲|COST910.18-5.56 (-0.61%) ▼|CRM249.12-10.11 (-3.90%) ▼|CSCO109.17-0.03 (-0.03%) ▼|CVS96.07-0.67 (-0.69%) ▼|CVX209.80+1.20 (+0.58%) ▲|DE680.73-12.80 (-1.85%) ▼|DHR205.23-2.43 (-1.17%) ▼|DIS105.06-0.25 (-0.24%) ▼|DUK121.24+1.02 (+0.85%) ▲|EMR152.15-0.67 (-0.44%) ▼|FDX314.13-8.39 (-2.60%) ▼|GD356.58-2.81 (-0.78%) ▼|GE334.91-2.21 (-0.66%) ▼|GEV971.31+29.36 (+3.12%) ▲|GILD146.64-4.36 (-2.88%) ▼|GM85.79-1.97 (-2.24%) ▼|GOOG335.38+0.07 (+0.02%) ▲|GOOGL338.36-0.10 (-0.03%) ▼|GS1,036.53-2.08 (-0.20%) ▼|HD313.70-7.35 (-2.29%) ▼|HON208.24-1.37 (-0.65%) ▼|IBM232.09-2.80 (-1.19%) ▼|INTC104.47+8.67 (+9.05%) ▲|INTU318.93-13.77 (-4.14%) ▼|ISRG350.16-16.54 (-4.51%) ▼|JNJ269.12-6.11 (-2.22%) ▼|JPM353.51-5.13 (-1.43%) ▼|KO88.36+0.29 (+0.33%) ▲|LIN468.38-9.19 (-1.92%) ▼|LLY1,123.91-25.45 (-2.21%) ▼|LMT536.15+10.87 (+2.07%) ▲|LOW200.80-3.65 (-1.79%) ▼|LRCX320.42+12.77 (+4.15%) ▲|MA570.89-8.32 (-1.44%) ▼|MCD255.81+0.12 (+0.05%) ▲|MDLZ61.63+0.35 (+0.57%) ▲|MDT92.39-1.78 (-1.89%) ▼|META613.48-3.29 (-0.53%) ▼|MMM167.52-1.04 (-0.62%) ▼|MO68.17-0.71 (-1.03%) ▼|MRK148.46-1.87 (-1.24%) ▼|MS216.24-1.48 (-0.68%) ▼|MSFT493.95-5.75 (-1.15%) ▼|MU1,000.26-16.33 (-1.61%) ▼|NEE83.83+0.40 (+0.48%) ▲|NFLX76.77-1.48 (-1.89%) ▼|NKE38.10-0.30 (-0.78%) ▼|NOW134.21-7.05 (-4.99%) ▼|NVDA225.73-4.63 (-2.01%) ▼|ORCL162.52+3.74 (+2.36%) ▲|PEP138.45+0.82 (+0.60%) ▲|PFE27.79-0.66 (-2.32%) ▼|PG145.58-0.86 (-0.59%) ▼|PLTR170.30-4.03 (-2.31%) ▼|PM184.73+2.20 (+1.21%) ▲|QCOM174.09+5.35 (+3.17%) ▲|RTX198.81-1.98 (-0.99%) ▼|SBUX102.01-2.46 (-2.35%) ▼|SCHW106.87-2.42 (-2.21%) ▼|SO88.99+0.88 (+1.00%) ▲|SPG211.88+2.44 (+1.17%) ▲|T25.60-0.08 (-0.31%) ▼|TMO603.02-10.76 (-1.75%) ▼|TMUS181.69+0.17 (+0.09%) ▲|TSLA368.16+14.08 (+3.98%) ▲|TXN258.92+0.48 (+0.19%) ▲|UBER73.13-2.63 (-3.47%) ▼|UNH400.84+3.70 (+0.93%) ▲|UNP288.45-1.17 (-0.40%) ▼|UPS100.48-1.81 (-1.77%) ▼|USB62.49-0.88 (-1.39%) ▼|V368.64-6.43 (-1.71%) ▼|VZ50.41+0.27 (+0.54%) ▲|WFC87.96-2.01 (-2.23%) ▼|WMT106.05-1.09 (-1.02%) ▼|XOM160.66+1.19 (+0.75%) ▲|
20.7 C
New York
Wednesday, September 9, 2026

Tag: hormone

newssourceFORcompanyinformationcontent1releasesmarket

Luma Nutrition Magnesium Glycinate Surpasses 10,000 Monthly Sales on Amazon

Los Angeles, CA , July 07, 2025 (GLOBE NEWSWIRE) -- Luma Nutrition is proud to announce that its flagship product, Luma Nutrition Magnesium Glycinate 1000mg, has officially surpassed 10,000 units sold per month on Amazon. As one of the best magnesium glycinate supplements available in 2025, this high-absorption formula continues to earn praise for its purity, effectiveness, and ability to support restful sleep, mental clarity, and full-body relaxation. 

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

Effective Testosterone Booster for Men Over 50: TestoPrime Medically Accredited as the Best Testosterone Supplement for Males In 40’s and 50’s

Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription 
Clinicians’ Choice Testosterone Booster: Medically Reviewed and Endorsed by Leading Experts, Now Available Nationwide Without Prescription

Direct Meds Launches Company-Wide AI Program to Scale Patient Care Amid Explosive Growth

Direct Meds LLC, a fast-scaling telemedicine provider serving the US and Canada, today announced a company-wide deployment of artificial intelligence (AI).

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

TORONTO, ONTARIO, June 30, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI; TSX: CSCI) (“COSCIENS” or the “Company”), a life sciences company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today announced the voting results on the items of business considered at the virtual annual general and special meeting of shareholders of the Company (the “AGSM”) held today.

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029, Highlighting Recurrent and Metastatic Innovations

"Metastatic Cancer: A Significant Therapeutic Challenge as Pharmaceutical Companies Leverage Digital Platforms and Data to Enhance Engagement with Patients, Providers, and Regulators in the...

Fit After 50, a Wellness-Focused Training System by Live Anabolic, Gains National Attention: Age-Defying Fitness Strategy Redefines Strength and Vitality for Men Over 50

Exploring the Growing Demand for Safe, At-Home Workouts That Support Strength, Hormonal Balance, and Longevity in Men Over 50 
Exploring the Growing Demand for Safe, At-Home Workouts That Support Strength, Hormonal Balance, and Longevity in Men Over 50

EU Good Food Debuts at SFH 2025, Strengthening Trade Links With Korean Food Market

SEOUL, South Korea, June 26, 2025 (GLOBE NEWSWIRE) -- The EU Good Food campaign proudly concluded its successful participation at Seoul Food & Hotel 2025 (SFH 2025), Asia’s leading international trade exhibition for the food and hospitality sector. Located at Stand 4D403, the EU pavilion offered a distinctive showcase of premium European agricultural products, demonstrating how these high-quality ingredients can elevate traditional Korean cuisine - enhancing flavor, nutritional value, and culinary refinement.

Olympia Pharmaceuticals Launches OlympiaYou.com: Empowering Patients Through Innovative Wellness and Sexual Health Support

OlympiaYou.com offers ED, weight loss, and wellness care with virtual pharmacists and discreet delivery, making health support more accessible.

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disease1 with an estimated global incidence of approximately 1 in 14,000–18,000 live births2A phase II...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHormone

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers